...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
【24h】

Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.

机译：树花粉提取物舌下免疫治疗儿童的临床疗效和安全性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Subcutaneous immunotherapy has been the principal approach of immunotherapy in the treatment of allergic diseases. Several clinical studies with birch, alder or hazel pollen extract conducted as subcutaneous immunotherapy have been published suggesting a well-tolerated and clinically effective treatment. Only a few clinical studies of sublingual immunotherapy (SLIT) with these allergens have been published. This study investigated the clinical efficacy, safety and dose-response relationship of SLIT in children suffering from rhinoconjunctivitis with/without asthma. Methods: Eighty-eight children (5-15 years) with a history of tree pollen-induced allergic rhinoconjunctivitis with/without seasonal asthma for >/=2 years were included. Allergy to tree pollen was confirmed by positive skin-prick test, positive specific IgE and positive conjunctival provocation test. The extract used was a glycerinated mixture of Betula verrucosa, Corylus avellana and Alnus glutinosa 100 000 SQ-U/ml. Children were randomized into three groups receiving SLIT 5 days a week for up to 18 months; dose group 1: accumulated weekly dose of 24 000 SQ-U; dose group 2: accumulated weekly dose of 200 000 SQ-U; and placebo. Results: In the birch pollen season, dose group 2 showed a significant reduction of symptom (P = 0.01) and medication scores (P = 0.04) compared with placebo. Dose group 1 showed a significant reduction of symptom scores (P = 0.03). There were no statistical differences between dose groups 1 and 2. All children tolerated the treatment well. Conclusion: SLIT with tree pollen extract provided dose-dependent benefits in tree pollen-allergic children in terms of significantly reduced symptoms and medication use. The treatment was well tolerated.
机译：背景：皮下免疫疗法一直是免疫疗法治疗过敏性疾病的主要方法。桦树，bi木或榛树花粉提取物作为皮下免疫疗法进行的几项临床研究已经发表，提示了耐受性良好且临床有效的治疗方法。关于这些过敏原的舌下免疫疗法（SLIT）的临床研究只有少数发表。这项研究调查了SLIT在患有/不患有哮喘的鼻结膜炎患儿中的临床疗效，安全性和剂量反应关系。方法：包括八十八例（5-15岁）有花粉诱导的变应性鼻结膜炎病史，有/没有季节性哮喘≥2年的儿童。通过皮肤点刺试验，特异性IgE阳性和结膜刺激试验阳性，证实对树花粉过敏。所使用的提取物是疣状桦，桔梗和Al木的甘油化混合物100 000 SQ-U / ml。将儿童随机分为三组，每周5天接受SLIT，长达18个月;剂量组1：每周累积剂量为24 000 SQ-U;剂量组2：每周累积剂量为20万SQ-U;和安慰剂。结果：在桦树花粉季节，与安慰剂相比，剂量组2的症状（P = 0.01）和药物评分（P = 0.04）明显降低。剂量组1的症状评分显着降低（P = 0.03）。剂量组1和2之间没有统计学差异。所有儿童对治疗的耐受性良好。结论：SLIT与树花粉提取物在显着减少症状和用药方面为树花粉过敏儿童提供了剂量依赖性的益处。治疗耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号